ReviewWorld journal of gastroenterology2012
Natural history of Barrett's esophagus.
Review in World journal of gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Guideline
- Clinical manifestations of gastrointestinal diseases in the oral cavity.The Saudi dental journal · 2021Review
- Barrett's oesophagus: Current controversies.World journal of gastroenterology · 2017Review
- Gastric adenocarinoma of the upper oesophagus: A literature review and case report.International journal of surgery case reports · 2017Article
- Two-year follow-up period showing the natural history of a superficial esophageal adenocarcinoma arising in a long segment of Barrett's esophagus.Clinical journal of gastroenterology · 2016Review
- Glottic cancer in a non-smoking patient with laryngopharyngeal reflux.Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia · 2016Article
- Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.Gastroenterology clinics of North America · 2015Review
- New Barrett's guidelines: an opportunity to improve patient experience and save resources.Frontline gastroenterology · 2015Article
- Barrett oesophagus: lessons on its origins from the lesion itself.Nature reviews. Gastroenterology & hepatology · 2015Review
- The impact of laparoscopic anti-reflux surgery in patients with Barrett's esophagus.Surgical endoscopy · 2014Article
- Risk factors associated with Barrett's epithelial dysplasia.World journal of gastroenterology · 2014Article
- Short-term Intervention to Revert Premalignant Lesions as Strategy to Prevent Gastrointestinal Cancers.Journal of cancer prevention · 2013Review
- Gastric reflux is an independent risk factor for laryngopharyngeal carcinoma.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2013Article
- Predictable Marker for Regression of Barrett's Esophagus by Proton Pump Inhibitor Treatment in Korea.Journal of neurogastroenterology and motility · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The natural history of Barrett's esophagus (BE) is difficult to quantify because, by definition, it should describe the course of the condition if left untreated. Pragmatically, we assume that patients with BE will receive symptomatic treatment with acid suppression, usually a proton pump inhibitor, to treat their heartburn. This paper describes the development of complications of stricture, ulcer, dysplasia and adenocarcinoma from this standpoint. Controversies over the definition of BE and its implications in clinical practice are presented. The presence of intestinal metaplasia and its relevance to cancer risk is discussed, and the need to measure the extent of the Barrett's epithelium (long and short segments) using the Prague guidelines is emphasized. Guidelines and international consensus over the diagnosis and management of BE are being regularly updated. The need for expert consensus is important due to the lack of randomized trials in this area. After searching the literature, we have tried to collate the important studies regarding progression of Barrett's to dysplasia and adenocarcinoma. No therapeutic studies yet reported show a clear reduction in the development of cancer in BE. The effect of pharmacological and surgical intervention on the natural history of Barrett's is a subject of ongoing research, including the Barrett's Oesophagus Surveillance Study and the aspirin and esomeprazole cancer chemoprevention trial with interesting results. The geographical variation and the wide range of outcomes highlight the difficulty of providing an individualized risk profile to patients with BE. Future studies on the interaction of genome wide abnormalities in Barrett's and their interaction with environmental factors may allow individualization of the risk of cancer developing in BE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.